No Data
Tianxin Pharmaceuticals (603235.SH): has repurchased 0.5961% of the shares accumulated.
On September 2, GeLongHui announced that as of August 31, 2024, the company has repurchased a total of 2,609,720 shares, accounting for 0.5961% of the total share capital. The highest repurchase price was 28.00 yuan/share, the lowest price was 19.17 yuan/share, and the total amount paid was 60,001,880.46 yuan (excluding transaction costs).
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Tianxin Pharmaceutical (603235.SH): The net income in the first half of the year was 0.345 billion yuan, a year-on-year increase of 4.61%.
GeLongHui August 30th | Tianxin Pharmaceutical (603235.SH) announced its semi-annual report for 2024. The company achieved revenue of 1.067 billion yuan in the first half of 2024, a decrease of 4.81% year-on-year; net income attributable to shareholders of the listed company was 0.345 billion yuan, an increase of 4.61% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.329 billion yuan, an increase of 3.73% year-on-year; basic earnings per share was 0.79 yuan.
Tianxin Pharmaceutical (603235.SH) released its performance for the first half of the year, with a net income of 345 million yuan, a year-on-year growth of 4.61%.
Tianxin Pharmaceutical (603235.SH) released its 2024 interim report, with a revenue of 1... during the reporting period.
These 4 Measures Indicate That JiangXi Tianxin Pharmaceutical (SHSE:603235) Is Using Debt Reasonably Well
No Data
No Data